IGPH.SW stock opened pre-market at CHF0.0015 on 27 Feb 2026, making IGEA Pharma (IGPH.SW) the most active name on SIX by volume. Trading shows 2,033,000 shares versus an average of 193,941, sending a +10.48 relative volume signal. The intraday range is CHF0.0015–0.0020 after a -25.00% move from the prior close. We review why liquidity spiked, how fundamentals read against the sector, and what model forecasts imply for traders and longer-term investors.

IGPH.SW stock intraday snapshot

Current quote: IGEA Pharma N.V. (IGPH.SW) on SIX is trading at CHF0.0015 in pre-market. Volume is elevated at 2,033,000 shares, far above the 50-day average of 193,941, signalling strong short-term interest.

Price context: the stock’s 52-week range is CHF0.0005–0.05 and moving averages sit at CHF0.00214 (50-day) and CHF0.00517 (200-day), underscoring the deep discount from prior levels.

Why the most active tag: liquidity and short-term drivers

One clear driver of the most active listing is liquidity: relative volume is 10.48, implying the market is absorbing unusually large orders. Market makers and momentum traders likely account for the burst in trades.

Catalysts to watch: corporate updates, lab-test sales notices, or OTC distribution news can move IGEA Pharma (IGPH.SW) given the company’s small float and 337,030,016 shares outstanding.

Fundamentals and valuation of IGPH.SW stock

IGEA Pharma shows distressed fundamentals: trailing EPS is -0.03 and reported P/E is -0.05, reflecting losses. Market cap is approximately CHF505,545, and the enterprise value sits near CHF2,103,032.44 according to TTM metrics.

Key ratios: current ratio is weak at 0.19, cash per share is 0.00009, and return on assets reads -52.65%, signalling capital constraints and elevated operational risk relative to the healthcare sector averages.

Technical and trading setup for short-term traders

Short-term technicals favour active trading, not buy-and-hold. The stock is below both the 50-day and 200-day averages, and intraday spread CHF0.0015–0.0020 suggests thin liquidity at narrow price levels.

Risk control: traders should use tight limit orders and size positions against available depth given the high relative volume and low absolute price.

Meyka AI rates IGPH.SW with a score out of 100 and forecast

Meyka AI rates IGPH.SW with a score out of 100: 62.62 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12-month model price of CHF0.00500, versus the current CHF0.00150, implying an upside of +233.33%. Forecasts are model-based projections and not guarantees.

Risks and potential catalysts for IGPH.SW stock

Primary risks include severe liquidity swings, negative working capital (-CHF977,400), and operating losses that pressure solvency. Small staff size and limited revenues raise execution risk for product rollouts.

Potential catalysts: clinical updates for the Alz1 test, new distribution agreements, or capital raises would materially change valuation and trading interest. Follow company filings and press updates on the corporate site.

Final Thoughts

IGPH.SW stock is a high-activity, high-risk ticker on SIX this pre-market session. At CHF0.0015, the share shows a sharp intraday move and a volume surge to 2,033,000 shares, driven by thin float dynamics and retail/momentum flows. Fundamentals are weak: negative EPS (-0.03), low current ratio (0.19), and constrained cash per share diminish margin for error. Meyka AI rates IGPH.SW at 62.62/100 (Grade B, HOLD) and the model projects CHF0.00500, an implied +233.33% from current levels; forecasts are model-based projections and not guarantees. For traders the setup is liquidity-driven; for investors the stock needs clear operational improvement or financing clarity before shifting to a buy stance. We link company filings and exchange data and will update as news arrives — monitor order books and corporate releases closely.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.